STOCK TITAN

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Xeris Biopharma to participate in fireside chat at Cantor Global Healthcare Conference
Positive
  • None.
Negative
  • None.

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Thursday, September 28, 2023 at 3:00pm Eastern Time.

A live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website at https://xerispharma.com/investor-relations or https://wsw.com/webcast/cantor19/xers/2124738

A replay of the webcast will be available for 60 days.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect™, to support long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or Instagram.

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

Source: Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

XERS Rankings

XERS Latest News

XERS Stock Data

481.27M
149.00M
3.91%
41.75%
7.76%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO